MIR143

Summary

MIR143 (microRNA 143, HGNC:31530) is a microRNA gene on chromosome 5q32.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 406935 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31530
Approved symbol	MIR143
Name	microRNA 143
Location	5q32
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-143
Ensembl gene	ENSG00000284182
Ensembl biotype	miRNA
OMIM	612117
Entrez	406935
RNAcentral	URS0000008A99 — miRNA, 106 nt, 9 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000385300

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000385300 — 1 exons

Exon	Start	End
ENSE00001500306	149428918	149429023

Expression profiles

Bgee: expression breadth broad, 31 present calls, max score 99.29.

Top tissues by expression

31 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
prostate gland	UBERON:0002367	99.29	gold quality
testis	UBERON:0000473	99.25	gold quality
uterus	UBERON:0000995	99.02	gold quality
epididymis	UBERON:0001301	98.28	gold quality
ovary	UBERON:0000992	98.08	gold quality
spleen	UBERON:0002106	97.78	gold quality
renal glomerulus	UBERON:0000074	95.35	gold quality
placenta	UBERON:0001987	94.14	gold quality
sural nerve	UBERON:0015488	91.98	gold quality
islet of Langerhans	UBERON:0000006	91.43	gold quality
midbrain	UBERON:0001891	89.13	gold quality
frontal lobe	UBERON:0016525	87.83	gold quality
pituitary gland	UBERON:0000007	82.59	gold quality
saliva-secreting gland	UBERON:0001044	75.02	gold quality
heart	UBERON:0000948	74.80	gold quality
right atrium auricular region	UBERON:0006631	74.74	gold quality
liver	UBERON:0002107	74.64	gold quality
blood	UBERON:0000178	69.42	gold quality
muscle of leg	UBERON:0001383	69.36	gold quality
gastrocnemius	UBERON:0001388	68.49	gold quality
body of stomach	UBERON:0001161	67.10	gold quality
putamen	UBERON:0001874	65.05	gold quality
skin of abdomen	UBERON:0001416	63.12	gold quality
body of pancreas	UBERON:0001150	59.16	gold quality
esophagus mucosa	UBERON:0002469	57.08	gold quality
hypothalamus	UBERON:0001898	52.41	gold quality
cerebellum	UBERON:0002037	50.74	gold quality
cerebellar hemisphere	UBERON:0002245	50.74	gold quality
thyroid gland	UBERON:0002046	49.37	gold quality
right hemisphere of cerebellum	UBERON:0014890	45.78	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NFKB, RREB1, SOX2

Literature-anchored findings (GeneRIF, showing 40)

• miR-143 is significant in suppressing colorectal cancer cell growth through inhibition of KRAS translation. (PMID:19137007)
• CK-8 and miR-143 expression were significantly higher in Barrett’s mucosa, before and after APC, whereas miRNA-205 and CK-14 expression was significantly lower in Barrett’s mucosa compared to all categories of squamous mucosa. (PMID:19190970)
• miR-143 and miR-145 may play a certain role in the development of colon and/or rectal cancers but not in progression of the disease. (PMID:19242066)
• Decreased expression of microRNA-143 is asociated with gastric cancers. (PMID:19439999)
• Up-regulation of miR-143 expression transcribed by NF-kappaB in hepatitis B virus-related hepatocellular carcinoma promotes cancer cell invasion/migration and tumor metastasis by repression of FNDC3B expression. (PMID:19472311)
• miR-143 regulates DNA methyltranferase 3A in colorectal cancer (PMID:19638978)
• ERK5 is a miR-143 target in prostate cancer (PMID:19855844)
• Findings suggest that miR-143 and -145 are important onco-related genes for the initiation step of colorectal tumor development and that the chemically modified synthetic miR-143 may be a candidate as an RNA medicine for colorectal tumor therapy. (PMID:20094072)
• data thus indicating the potential of miR-21, miR-143 and miR-181a as a novel diagnostic or prognostic biomarker for non small cell lung cancer. (PMID:20363096)
• data demonstrate that the host gene can function as a primary miRNA transcript and suggest that the down-regulation of host gene expression caused the low-expression of its encoded microRNAs-143 and -145 in human cancer cell lines and in cancer tissues (PMID:20525177)
• a higher expression of miR-21 and lower expression of miR-143 in colorectal cancer tissue in comparison with adjacent normal colon tissue (P < 0.0001; P < 0.0001, respectively). (PMID:20620599)
• Results suggest a possible causal relation between increased expression of miR-143 and neuroblastoma in hypoxic conditions (PMID:20809117)
• KRAS and RREB1 are targets of miR-143/miR-145, revealing a feed-forward mechanism that potentiates Ras signaling (PMID:21159816)
• miR-143 plays an important role in prostate cancer proliferation, migration and chemosensitivity by suppressing KRAS and subsequent inactivation of MAPK pathway. (PMID:21197560)
• These findings suggest that the deregulation of miRNAs plays an important role in the progression of esophageal squamous cell carcinoma (ESCC), and that both miR-143 and miR-145 might act as anti-oncomirs common to ESCC. (PMID:21218087)
• The high levels of expression of mature MIR143 were associated with recurrence of metastasis in ESCC patients (PMID:21453382)
• Expression of miR-143 in bone marrow cells of acute leukemia patients is down-regulated. (PMID:21518477)
• findings suggest that the chemically-modified synthetic miR-143 functions as a tumor suppressor in T24 cells by targeting ERK5 and/or Akt (PMID:21550168)
• miR-143 is downregulated in ulcerative colitis. (PMID:21557394)
• miRs-143 and -145 are associated with bone metastasis of prostate cancer (PMID:21647377)
• down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. (PMID:21673106)
• miR-143/145 as activated independently by Jag-1/Notch and SRF in parallel pathways. (PMID:21685392)
• Restoring miR-143 expression in dedifferentiated liposarcoma cells inhibited proliferation, induced apoptosis. (PMID:21693658)
• Data found expression of miR-143/145 cluster in human corneal epithelium. (PMID:21701675)
• miR-143 functions as a tumor suppressor in MLL-AF4 B-cell acute lymphoblastic leukemia. (PMID:21706045)
• microRNA-143 protects cells from DNA damage-induced killing by downregulating FHIT expression (PMID:21711110)
• a dual pathway for TGF-beta1-induced transcription of miR143/145, thus revealing a novel mechanism underlying TGF-beta1-induced human vascular SMC differentiation. (PMID:21712382)
• Expression of miR-143 to be low in a series of human bladder carcinomas as compared to background tissue. (PMID:21790228)
• Quantity of micro-RNA/143 decreases in media and intima of coronary artery during restenosis progression. (PMID:21943005)
• Down-regulation of miR-143 is associated with acute myeloid leukemia. (PMID:22093444)
• demonstrate mRNA co-targeting by a cluster of non-family miRNAs, and suggest miR-145 and PAI-1 as clinically relevant biomarkers in bladder cancer (PMID:22108519)
• The miR-143 suppressed the activity of a luciferase reporter carrying the 3’-UTR of Bcl-2, which was abolished by mutation of the predicted miR-143-binding site, indicating that Bcl-2 is a miR-143 target gene. (PMID:22160209)
• The expression of mir-21 and mir-143 were measured in 142 formalin-fixed, paraffin embedded (FFPE) cervical biopsy tissue blocks. (PMID:22194833)
• Data show that extracellular vesicles secreted by KLF2-transduced or shear-stress-stimulated umbilical vein endothelial cells (HUVECs) are enriched in miR-143/145 and control target gene expression in co-cultured smooth muscle cell (SMC). (PMID:22327366)
• findings suggest that MDM2 dysregulation caused by downregulation of miR-143 and miR-145 contributes to epithelial cancer development and has a key role in regulating cellular proliferation and apoptosis (PMID:22330136)
• Via targeting C/EBPbeta (a transcriptional activator for mir-143), miR-155 represses mir-143, a negative regulator of hk2, thus resulting in upregulation of hk2 expression at the post-transcriptional level. (PMID:22354042)
• protein level of FSCN1 showed no significant linear correlation with miR-143 and miR-145 expression in ESCC cell lines with Western blotting analysis (PMID:22457808)
• All these data unveil a new miRNA-dependent mechanism of regulation of hexokinase expression (PMID:22469988)
• Findings newly described miR-143/MACC1 link and provided a potential mechanism for MACC1 dysregulation and contribution to CRC cell invasion. (PMID:22533346)
• miRNA-143 represents a novel prognosticator and a promising drug target for patients with colorectal cancer (PMID:22549179)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	dre-mir-143	ENSDARG00000082513
mus_musculus	Mir143	ENSMUSG00000065445

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.